This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B23.1 (Persistent generalized lymphadenopathy) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | Persistent generalized lymphadenopathy (PGL); HIV-associated lymphadenopathy; AIDS-related complex (ARC) — former term; Lymphadenopathy syndrome (LAS) |
| C. Adult onset | Likelihood of onset in adulthood: Very high — HIV-associated persistent generalized lymphadenopathy is a characteristic finding in the asymptomatic chronic HIV infection stage. It persists for months to years after acute infection, mainly in adults with HIV infection, and reflects systemic immune activation and a sustained immune response to HIV. |
| 1. History | First described in 1982. In the era before HIV antibody testing, recognized as a marker of the "pre-AIDS" stage. In 1983, a component of the "AIDS-related complex (ARC)". Now reclassified as the clinical expression of asymptomatic chronic HIV infection. |
| 2. Causes | Sustained B-cell and T-cell immune response to HIV antigens. Accumulation of HIV on follicular dendritic cells (FDC) in lymph nodes. Lymph node hyperplasia due to chronic immune activation. Co-infection with viruses such as EBV and CMV also contributes. |
| 3. Genetics | Not a hereditary disease. HLA type influences the intensity of immune activation and the duration of PGL. IL-10 polymorphisms: alleles with high IL-10 expression may promote B-cell proliferation and lymph node hyperplasia. |
| 4. General epidemiology | PGL is observed in about 50-70% of asymptomatic persons with HIV. It develops within months after HIV infection and persists for years before ART. After starting ART, lymph node size decreases within 6-12 months in most. It is most common when the CD4 count is maintained (200-500/μL). |
| 5. Pathophysiology | Sustained B-cell activation and follicular hyperplasia in response to HIV antigens → accumulation of HIV on follicular dendritic cells (FDC) in lymph nodes → disruption of lymph node architecture. Early: follicular hyperplasia. Late: follicular involution → lymph node atrophy. |
| 6. Symptoms | Mostly asymptomatic. Many patients present with lymph node enlargement (2 cm or larger, at 2 or more sites, lasting 3 months or longer) as the only chief complaint. Intermittent fatigue, night sweats, and low-grade fever may accompany it. Lymph node pain is rare. |
| 7. Signs | Symmetric enlargement of cervical, axillary, and inguinal lymph nodes (1-3 cm in diameter, mobile, non-tender). Mediastinal and hilar lymph node enlargement is possible on chest CT. Blood: hyperimmunoglobulinemia, moderately decreased CD4, positive HIV RNA. Tissue: follicular hyperplasia (early) or follicular involution (late). |
| 8. Screening | At regular examinations of persons with HIV, assess lymph node size, consistency, and distribution. For non-tender lymph node enlargement persisting 3 months or longer, consider HIV-associated PGL first. Regularly follow changes in lymph node size. Biopsy if findings suggest malignant lymphoma (rapid increase in size, hardening, B symptoms). |
| 9. Diagnosis | CDC definition: HIV infection + lymph node enlargement of 1 cm or more at 2 or more extrainguinal sites + persisting 3 months or longer + exclusion of other causes. Biopsy is performed when differentiating lymphoma, tuberculosis, MAC, etc. Histopathology: follicular hyperplasia (early) or follicular involution (late). |
| 10. Treatment | PGL itself is not a direct indication for ART. When ART is started, lymph node enlargement decreases spontaneously as immune activation falls and HIV replication is suppressed. If there are no symptoms other than lymph node enlargement, observe the course. If an underlying infection or tumor is found, apply the corresponding treatment. |
| 11. Prognosis | PGL itself has a benign course. Most cases improve after ART. However, if PGL progresses to follicular involution (sharp CD4 decline, increased viral load), it is a warning sign of AIDS progression. In some patients with PGL, the risk of non-Hodgkin lymphoma on long-term follow-up is higher than in the general population. |
| 12. Prevention | Minimize chronic immune activation through early HIV diagnosis and ART. There is no specific prevention for PGL itself, but early ART minimizes destruction of lymph node architecture caused by immune activation. |
| 13. References | Includes 10 key references |
HIV-associated persistent generalized lymphadenopathy (PGL) was first described in the United States in 1982, in the early AIDS epidemic. At that time, PGL was reported as a prominent finding in a clinical group who experienced symptoms associated with gay-related immune deficiency (GRID) or AIDS but had no AIDS-defining opportunistic infection or malignancy.
In 1983 this syndrome was included in the clinical category "AIDS-related complex (ARC)," and PGL was recognized as a component of ARC together with fever, night sweats, fatigue, and weight loss. ARC was understood as an intermediate state progressing to AIDS, but because it preceded the discovery of HIV, the exact cause was unknown.
After the HIV antibody test was developed in 1984-1985, patients with PGL were confirmed to be HIV antibody positive, making it clear that PGL is a clinical expression of HIV infection. In its 1986 HIV infection classification system, the CDC included PGL as a feature of asymptomatic HIV infection (Group II) and chronic lymphadenopathy (Group III).
In the late 1980s to early 1990s, the histopathologic characteristics of PGL were elucidated. Follicular hyperplasia of lymph nodes is a feature of early PGL, and it was found that the process in which follicles become involuted over time and the lymph node eventually atrophies is associated with AIDS progression. It was also established in this period that HIV antigen-antibody complexes accumulate on follicular dendritic cells (FDC), so that lymph nodes serve as an important reservoir of HIV.
Since ART in 1996, PGL most often shows a benign course in which lymph nodes disappear or shrink in response to treatment. However, early after starting ART, transient worsening of lymph node enlargement may occur as IRIS. At present, PGL is a characteristic finding of the asymptomatic chronic infection stage in the clinical spectrum of HIV infection, and is used as an important clinical indicator in evaluating HIV infection.
HIV-associated persistent generalized lymphadenopathy is the result of chronic immune activation and sustained antigenic stimulation by HIV infection causing an excessive response within lymph nodes.
Sustained stimulation by HIV antigens: HIV continues to replicate in lymph nodes even after seroconversion, and HIV antigens accumulate on the surface of follicular dendritic cells (FDC). FDCs capture HIV immune complexes (HIV antigen + antibody) and continuously present them to B cells. As a result, B-cell follicles are excessively activated, leading to germinal center formation and follicular hyperplasia.
Chronic immune activation: Systemic immune activation by HIV infection (elevated T-cell activation markers CD38 and HLA-DR) promotes T-cell proliferation within lymph nodes. Influx of microbial products such as lipopolysaccharide (LPS) into the blood due to bacterial translocation causes nonspecific B-cell activation. Proinflammatory cytokines such as IL-6, TNF-α, and IL-1β accelerate cell proliferation within lymph nodes.
Co-infection with other viruses: EBV infects B cells and promotes polyclonal B-cell proliferation. Latent infection with CMV and Kaposi sarcoma-associated herpesvirus (HHV-8) also contributes to lymph node hyperplasia. HHV-8-associated multicentric Castleman disease (MCD) causes lymph node enlargement similar to PGL, so differentiation is important.
Stages of lymph node architectural change: Early (CD4 >500/μL): follicular hyperplasia predominates. Middle (CD4 200-500/μL): follicular hyperplasia continues, increased accumulation of HIV RNA on FDCs. Late (CD4 <200/μL): follicular involution, vascular proliferation, and increased connective tissue cause lymph node atrophy and functional decline. These late changes are a poor prognostic indicator of HIV progression.
PGL is not a hereditary disease, but host immune gene polymorphisms influence the intensity and character of the lymph node response.
HLA type: HLA molecules determine the immune presentation of HIV antigens and thereby govern the quality and intensity of the HIV-specific T-cell response. In carriers of HLA-B*57:01, an efficient HIV-specific CD8+ T-cell response is induced, and HIV replication within lymph nodes may be better suppressed. HLA-DR alleles influence the degree of B-cell follicular hyperplasia through CD4+ T helper cell responses.
IL-10 polymorphism: IL-10 is an anti-inflammatory cytokine that promotes B-cell survival and proliferation. The IL-10 promoter -1082G allele increases IL-10 expression and may further promote B-cell hyperproliferation and lymph node enlargement. A high-IL-10 phenotype in persons with HIV may be associated with hyperimmunoglobulinemia and increased risk of B-cell lymphoma.
CCR5 polymorphism: CCR5-Δ32 heterozygotes partially suppress HIV replication, which may reduce the HIV antigen load in lymph nodes and lessen the severity of PGL. However, once PGL has developed, the direct association between CCR5 genotype and lymph node architectural change is limited.
FcγR polymorphism: Fcγ receptor (FcγRIII, CD16) polymorphisms affect the ability of NK cells and macrophages to phagocytose HIV immune complexes. The efficiency of clearing HIV immune complexes accumulated on FDCs may vary with FcγR polymorphism, which may affect HIV accumulation in lymph nodes and the duration of PGL.
HIV-associated PGL is one of the most common clinical expressions of asymptomatic chronic HIV infection, and its epidemiologic characteristics are closely related to the clinical stage of HIV infection.
Prevalence: PGL was observed in about 50-70% of asymptomatic persons with HIV before ART. The prevalence of PGL has decreased since the introduction of ART, but mild lymph node enlargement persists in some patients even during ART. It is most common in persons with chronic HIV infection whose CD4+ T-cell count is in the range of 200-500/μL.
Time of onset: PGL begins to appear within weeks to months after the acute syndrome subsides following HIV infection. In some patients, lymph node enlargement persists after the acute infection syndrome and transitions to PGL. In patients not treated with ART, PGL can persist for years to decades.
CD4 level and PGL stage: CD4 >500/μL (early asymptomatic): follicular hyperplasia predominates. CD4 200-500/μL (chronic asymptomatic phase): follicular hyperplasia or mixed type. CD4 <200/μL (after the pre-AIDS stage): follicular involution, lymph node atrophy. Lymph node atrophy is an indicator of AIDS progression, and at this stage a paradoxical phenomenon is observed in which lymph nodes actually become smaller.
Age and sex: There is no sex difference in adults. The younger the age at HIV infection (adolescents, young adults), the higher the capacity for immune activation and the more prominent the PGL tends to be. In older persons with HIV, the PGL response may be less pronounced because of immunosenescence.
The pathophysiology of PGL centers on an excessive B-cell response to HIV antigens and accumulation of HIV on FDCs, and is characterized by a stepwise process that progresses over time from follicular hyperplasia to follicular involution.
Early stage: follicular hyperplasia: HIV antigens are captured through the bloodstream by the follicular dendritic cell (FDC) network of systemic lymph nodes. FDCs retain HIV antigen-antibody complexes on their surface for a long time and continuously present antigen to germinal center B cells. In response, the germinal center reaction is activated and the germinal centers expand greatly. Histologically, follicular hyperplasia appears, with a marked increase in secondary follicles having large germinal centers. At this stage the lymph nodes are enlarged, large, and soft.
Progressive stage: mixed type and FDC degeneration: With continued stimulation by HIV antigens, the FDC network begins to be damaged. Germinal centers become irregular, and loss of lymphocytes around the germinal centers begins. Because HIV is accumulated in large quantities on the FDC surface, FDCs become the most important HIV reservoir within lymph nodes. Loss of CD4+ T cells within lymph nodes progresses.
Late stage: follicular involution: With sustained immune activation, the FDC network is destroyed and germinal centers are exhausted. Histologically, loss of germinal centers, loss of lymphocyte compartments, vascular hyperplasia, and fibrosis are characteristic. At this stage lymph nodes actually become smaller or harder. Lymph node function is markedly reduced, and antigen presentation and B-cell differentiation become impossible. This follicular involution stage occurs at CD4 <200/μL and is a precursor of AIDS progression.
Contribution of bacterial translocation: Bacterial translocation increases because of HIV-induced collapse of intestinal mucosal immunity, and substances of microbial origin (LPS, peptidoglycan) enter the bloodstream. These nonspecifically stimulate B cells and dendritic cells through TLR (Toll-like receptor) signaling pathways, further promoting lymph node hyperplasia.
PGL itself is mostly asymptomatic or mild, and is often found incidentally or confirmed during examination for other reasons.
Lymph node enlargement: The most characteristic finding. Non-tender lymph node enlargement appears symmetrically at multiple superficial sites, including the neck (including the posterior cervical region), axilla, and groin. Lymph node size is generally 1-3 cm, and the nodes are mobile with a soft or rubbery feel. The lymph nodes do not adhere to one another and are not fixed to the skin.
Mild systemic symptoms: In some patients, mild fatigue, night sweats (relatively mild), and low-grade fever (37.5-below 38℃) appear intermittently. These symptoms are nonspecific and reflect the systemic immune activation of chronic HIV infection. If symptoms are severe or persistent, other causes (opportunistic infection, malignancy) must be excluded.
Without lymph node symptoms: Many patients with PGL have no symptoms other than lymph node enlargement, appearing as an extension of asymptomatic chronic HIV infection. Therefore, the diagnosis of PGL itself is sometimes the first clue to HIV infection.
Warning symptoms (suggesting a malignant course): The following findings suggest secondary causes such as lymphoma, tuberculosis, MAC, and Kaposi sarcoma and require immediate evaluation: (1) rapid increase in lymph node size, (2) hardening or adhesion of lymph nodes, (3) B symptoms (fever ≥38℃, night sweats, weight loss of 10% or more within 6 months), (4) tenderness and localized pain, (5) asymmetric lymph node enlargement at a single site.
Physical examination findings of lymph nodes: Enlarged cervical (posterior cervical, lateral cervical, subclavian), axillary, and inguinal lymph nodes are palpated symmetrically at 2 or more extrainguinal sites. Lymph node size: 1-3 cm in diameter (1 cm or more by PGL criteria). Feel: non-tender, mobile, soft or rubbery. No skin changes and no adhesion to the overlying skin. Hepatosplenomegaly accompanies in some patients.
Imaging findings: Abdominal ultrasound or CT: mesenteric and intra-abdominal lymph node enlargement. Chest CT: mediastinal and hilar lymph node enlargement is possible. PET-CT: FDG uptake is mildly to moderately increased, which helps differentiate from malignant lymphoma (SUV max 2-4 in PGL; generally higher in lymphoma).
Blood and immunologic findings: Positive HIV RNA (quantitative). Moderately decreased CD4+ T-cell count (200-500/μL is typical). Inverted CD4/CD8 ratio (<0.5). Serum immunoglobulins: polyclonal hypergammaglobulinemia, with IgG, IgA, and IgM all increased. Elevated β₂-microglobulin reflects immune activation. Mild elevation of serum LDH is possible.
Lymph node histopathology: PGL is confirmed by histologic findings on biopsy. Early: extensive increase in secondary follicles with large germinal centers (follicular hyperplasia). Progressive stage: irregularity of germinal centers, loss of surrounding follicular cells, vascular proliferation. Late: loss of germinal centers, follicular involution, lymphocyte depletion, fibrosis. HIV accumulation on FDCs can be confirmed with HIV p24 antigen immunohistochemical staining.
Screening for PGL is done through regular physical examination of all persons with HIV, and systematic monitoring of lymph node changes is important.
Regular lymph node assessment: In all persons with HIV, palpate the cervical, axillary, and inguinal lymph nodes at every outpatient visit. Record newly appearing lymph node enlargement or changes in the size of existing lymph nodes. If the diameter is 1 cm or more and persists for 3 months or longer, confirm whether the PGL diagnostic criteria are met.
Screening tests for differential diagnosis: If fever is present or B symptoms accompany, perform the following tests: (1) chest X-ray/CT to check for mediastinal and hilar lymph node enlargement and lung infiltrates; (2) abdominal ultrasound/CT to assess intra-abdominal lymph node enlargement; (3) blood tuberculosis test (IGRA); (4) CMV pp65 antigenemia; (5) EBV VCA IgM/IgG; (6) serum cryptococcal antigen; (7) LDH, β₂-microglobulin (indicators of malignant lymphoma).
Indications for lymph node biopsy: Perform lymph node biopsy in the following cases: (1) B symptoms (fever ≥38℃, night sweats, weight loss of 10% or more within 6 months); (2) rapid increase in lymph node size; (3) sclerotic, adherent lymph nodes; (4) asymmetric enlargement at a single site; (5) high FDG uptake on PET-CT (SUV max >4-5); (6) new lymph node enlargement at CD4 <100/μL (possible opportunistic infection).
The diagnosis of PGL is made by meeting the CDC definition criteria while excluding other causes.
CDC diagnostic criteria for PGL: All of the following 3 must be met. (1) Confirmed HIV infection (positive HIV antibody or RNA). (2) Lymph node enlargement of 1 cm or more at 2 or more extrainguinal sites (including cervical, axillary, posterior cervical, preauricular/postauricular, infra-auricular, occipital, medial upper arm, and popliteal lymph nodes). (3) Persisting 3 months or longer. (4) Not explained by other causes (infection, malignancy, drug reaction).
Differential diagnosis of lymph node enlargement: The causes of lymph node enlargement in persons with HIV are varied. PGL (reactive hyperplasia): the most common and generally benign. Malignant lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma): suggested by B symptoms and rapid increase in size. Tuberculosis or MAC infection: accompanied by fever, night sweats, and weight loss. Cryptococcosis: headache, meningitis symptoms. Kaposi sarcoma: accompanied by skin and mucosal lesions. CMV lymphadenitis: accompanied by CMV viremia. Secondary syphilis: rash, mucosal lesions.
Interpretation of lymph node biopsy histopathology: On biopsy, follicular hyperplasia and follicular involution are distinguished by light microscopy findings. Assess T/B-cell distribution and clonality with immunohistochemical staining. Confirm HIV accumulation within FDCs with HIV p24 antigen or HIV RNA in situ hybridization. Includes tuberculosis AFB stain, MAC culture, fungal culture, and EBV EBER ISH.
There is no specific treatment for PGL itself, and ART for HIV itself is effective in improving PGL.
Initiation of ART: Current guidelines recommend immediate initiation of ART in all persons with HIV regardless of the presence of PGL. When HIV RNA suppression and CD4 recovery are achieved by ART, PGL improves within 6-12 months in most. Lymph node size decreases gradually over several months after starting ART.
IRIS precautions: Within 4-8 weeks of starting ART, IRIS (lymph node IRIS) with transient worsening of lymph node enlargement may occur. Lymph node IRIS mostly improves spontaneously and does not require special treatment. However, if there is abrupt worsening of lymph node enlargement and fever, differentiate whether it is IRIS, lymphoma, or tuberculosis reactivation.
Treatment of underlying causes: When the cause of PGL is tuberculosis, MAC, or lymphoma rather than simple reactive hyperplasia, apply the standard treatment of the corresponding disease. Malignant lymphoma: chemotherapy ± radiation therapy. Tuberculosis: isoniazid + rifampin + ethambutol + pyrazinamide. MAC: clarithromycin + ethambutol. HHV-8-associated multicentric Castleman disease (MCD): rituximab-based treatment.
Follow-up observation: PGL without findings suggesting a malignant course is followed with regular lymph node size measurement. If the lymph nodes have not decreased significantly or have even enlarged 6 months after starting ART, re-evaluate.
PGL itself has a benign course and mostly improves in patients who respond to ART. However, the histologic stage of PGL has prognostic significance as an indicator of HIV progression.
Prognosis with ART response: In about 80-90% of patients who respond to ART, PGL improves within 12 months. When HIV RNA suppression and CD4 recovery are achieved, lymph nodes return to normal size or disappear. In ART-refractory patients, PGL progresses to follicular involution and lymph node function declines.
PGL as a predictor of AIDS progression: Pathologic findings of the follicular involution stage of lymph nodes are pathologic indicators of CD4 decline and AIDS progression. Clinically, "paradoxical lymph node loss," in which lymph nodes actually become smaller, can be a precursor symptom of AIDS progression. When progression to the involution stage occurs, the immune response to opportunistic infection becomes even more vulnerable because of reduced antigen-presenting capacity.
Risk of lymphoma: According to long-term follow-up studies in patients with PGL, the risk of non-Hodgkin lymphoma is increased about 60- to 100-fold compared with the general population. This is because persistent chronic B-cell hyperactivation creates the basis for lymphoma development. The risk of lymphoma has decreased since ART, but remains higher than in the general population.
Early HIV diagnosis and ART: To prevent progression of PGL, HIV infection must be diagnosed early and ART started immediately to minimize chronic immune activation. The higher the CD4 level at which ART is started, the more the progression from follicular hyperplasia to follicular involution is suppressed.
Regular monitoring: Even in persons with HIV on ART, monitor for new lymph node enlargement or changes in existing enlargement through regular lymph node examination. If there are findings suggesting malignant lymphoma, perform a biopsy immediately for early diagnosis.
Management of EBV and HHV-8: Maintaining immune function with ART is the most effective way to suppress EBV and HHV-8 reactivation. In HHV-8 seropositive persons with HIV, monitoring of the risk of developing MCD is needed when CD4 declines.
Considerations for lymphoma prevention: Suppressing chronic B-cell activation by maintaining ART is important for preventing lymphoma. More active monitoring is needed in patients with risk factors for lymphoma (high EBV titer, older age, immunosuppression).